If You Invested in NetraMark Holdings Inc (AINMF)

NetraMark Holdings Inc. (OTCQB: AINMF) is described as a premier artificial intelligence (AI) company that is transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry. The company is also listed on the Canadian Securities Exchange under the symbol AIAI and on the Frankfurt exchange under the symbol PF0. NetraMark focuses on applying Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) to pharmaceutical research and development, with a particular emphasis on clinical trial design, interpretation, and optimization.

According to the company, its core offering is the proprietary NetraAI platform. NetraAI is characterized as an explainable, mathematically augmented AI/ML system that uses a novel topology-based algorithm to parse patient datasets into subsets of people that are strongly related across several variables simultaneously. This approach is designed to separate small, complex datasets into "explainable" and "unexplainable" subsets. The explainable subsets are then used to derive insights and hypotheses, including factors that influence treatment response, placebo response, and adverse events in clinical trials.

NetraMark states that this methodology can work effectively with much smaller datasets than many traditional AI methods. By identifying high-effect-size subgroups and segmenting diseases into different types, NetraAI is intended to accurately classify patients for sensitivity to drugs and the efficacy of treatment. The company positions this explainability as important for clinical investigators, regulators, and sponsors who require interpretable outputs rather than opaque "black box" models.

Business focus and pharmaceutical applications

NetraMark describes its business focus as the development of Gen AI/ML solutions targeted at the pharmaceutical industry. Its technology is applied to clinical data from late-stage trials, including Phase II and Phase III programs, to uncover and characterize patient subpopulations that drive therapeutic response and overall trial variability. The company reports engagements with global pharmaceutical and biopharmaceutical companies, including repeat business under master services agreements, to support analytics for pivotal clinical trials.

Across multiple announcements, NetraMark highlights the use of NetraAI in areas such as major depressive disorder, treatment-resistant depression, psychiatric indications, oncology, glioblastoma, and complex pain. In these contexts, NetraAI is used to identify explainable patient personas or subgroups, analyze treatment and placebo-response patterns, and support evidence-based decision-making for clinical, regulatory, and market access planning. The company also notes collaborations with academic and research institutions, including psychiatric and oncology research programs, where NetraAI is deployed within secure computing environments to analyze genetic, epigenetic, and proteomic data.

NetraAI platform characteristics

NetraAI is repeatedly described as including focus mechanisms that separate small datasets into explainable and unexplainable subsets. Unexplainable subsets are defined as collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. By contrast, the explainable subsets are used to derive insights and hypotheses that may increase the chances of clinical trial success. Many other AI methods, according to the company, lack these focus mechanisms and assign every patient to a class, which can lead to overfitting and loss of critical information.

The platform is also described as using a topology-based algorithm and a dynamical systems framework, along with long-range memory mechanisms and feature learning. These elements are presented as enabling NetraAI to discover stable, clinically interpretable subgroups within heterogeneous datasets. In published and presented work, NetraAI has been applied to identify responder and non-responder subgroups, placebo-associated participants, and highly predictive responder groups defined by specific clinical or molecular features.

Scientific, clinical, and regulatory engagement

NetraMark reports several forms of external engagement around its technology. A peer-reviewed paper describing the NetraAI platform and its application to a Phase II depression trial has been accepted for publication in npj Digital Medicine, part of the Nature Portfolio. The study demonstrates how NetraAI identified interpretable patient personas or model-derived subgroups that may inform precision-enrichment strategies in psychiatry and other therapeutic areas.

The company also describes scientific collaboration with organizations such as the U.S. National Institute of Mental Health (NIMH) and the Centre for Addiction and Mental Health (CAMH). In these collaborations, NetraAI is used to analyze clinical, genomic, and epigenetic datasets in disorders such as schizophrenia and major depressive disorder, with the goal of identifying explainable patient subpopulations and clarifying biological subtypes.

On the regulatory side, NetraMark has completed a Critical Path Innovation Meeting (CPIM) with the U.S. Food and Drug Administration (FDA). The company explains that this CPIM was a non-regulatory, non-binding scientific exchange in which the FDA provided feedback on NetraAI’s approach as a potential enrichment methodology in clinical trial design. The FDA discussion included topics such as pre-specified, α-controlled predictive enrichment, responder-enriched subgroups, and control of Type I error, in the context of FDA enrichment guidance. The company notes that CPIM discussions do not constitute FDA endorsement of NetraAI or any product or service.

Collaborations and research initiatives

NetraMark has announced multiple collaborations and contracts that illustrate how it applies NetraAI in practice. These include:

• Contracts with leading global pharmaceutical and biopharmaceutical companies to apply NetraAI to multiple late-stage clinical studies, including Phase III trials of psychiatric medicines.
• A research collaboration with CAMH, supported by an Ontario Research Fund – Research Excellence Award, in which NetraAI is deployed to analyze genetic and epigenetic data in schizophrenia and major depressive disorder.
• A collaboration focused on glioblastoma research with a U.S. academic medical center, where NetraAI is applied to longitudinal cerebrospinal fluid proteomic datasets to identify patient subgroups and potential biomarkers relevant to future clinical trials.
• Presentations at scientific conferences such as the International Society for CNS Clinical Trials and Methodology (ISCTM) and the European College of Neuropsychopharmacology (ECNP), demonstrating NetraAI’s use in major depressive disorder trials and its ability to address issues such as functional unblinding and heterogeneous treatment response.

Through these activities, NetraMark positions NetraAI as a tool for generating explainable insights from complex clinical datasets, supporting precision-enrichment strategies, and informing trial design and interpretation in central nervous system (CNS) and oncology indications.

Capital markets and financing

NetraMark Holdings Inc. trades in the United States on the OTCQB under the symbol AINMF, in Canada on the CSE under AIAI, and in Frankfurt under PF0. The company has announced a non-brokered private placement financing of units consisting of common shares and common share purchase warrants. According to the company, the net proceeds are intended for general working capital and corporate purposes, including continued advancement and commercialization of the NetraAI platform and support of ongoing and prospective biopharmaceutical engagements.

In its disclosures, NetraMark also refers to a non-IFRS financial measure called "contract backlog," defined as the total revenue associated with signed contracts for NetraAI services where services have not been completed and revenue has not yet been recognized under IFRS. The company states that contract backlog provides visibility into committed future revenue from signed contracts, while noting that it is not a standardized measure and should not be considered a substitute for IFRS measures.

Position within the information and software sector

NetraMark is categorized in the information sector, within the software publishers industry. Its activities center on developing and applying specialized AI software for pharmaceutical and biopharmaceutical clients, research institutions, and clinical trial sponsors. Rather than focusing on general-purpose software, the company emphasizes explainable AI tailored to clinical development, with a particular focus on small, heterogeneous datasets and the identification of clinically meaningful patient subgroups.

According to its public communications, NetraMark aims to align its technology with evolving expectations for explainable AI in clinical development and regulatory science. By embedding explainability, reproducibility, and traceability into its platform, the company seeks to provide tools that can be used in the context of regulatory guidance on enrichment strategies and model credibility.

Use cases and example applications

Across its announcements, NetraMark describes several concrete use cases for NetraAI, including:

• Identifying responder, non-responder, and placebo-associated patient subpopulations in Phase II and Phase III trials.
• Clarifying whether treatment effects are driven by true pharmacologic signals versus placebo or expectancy effects, as illustrated in ketamine trials for major depressive disorder.
• Reducing the dimensionality of complex clinical and molecular datasets to compact, interpretable feature sets that improve prediction of treatment response.
• Discovering biologically grounded responder subgroups characterized by specific genetic or epigenetic signatures.
• Supporting trial enrichment strategies, stratified randomization, and patient selection approaches in CNS and oncology research.

These use cases are presented as examples of how NetraAI can help sponsors and researchers better understand heterogeneous patient populations and design more targeted and efficient clinical trials.

Summary

In summary, NetraMark Holdings Inc. is an AI-focused software company in the information sector, with a stated mission of transforming pharmaceutical clinical trials through explainable, mathematically grounded AI and machine learning. Through its NetraAI platform, collaborations with pharmaceutical companies and research institutions, and engagement with scientific and regulatory communities, the company concentrates on precision analytics that aim to improve the interpretation and design of clinical studies, particularly in psychiatry and oncology.